CCX168

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Conditions

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Trial Timeline

Dec 3, 2015 → May 25, 2016

NCT ID

NCT05988021

About CCX168

CCX168 is a phase 1 stage product being developed by Amgen for Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05988021. Target conditions include Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis.

What happened to similar drugs?

0 of 1 similar drugs in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis were approved

Approved (0) Terminated (0) Active (1)

🔄Rituximab + AzathioprineRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05988021	Phase 1	Completed	Dec 3, 2015	May 25, 2016	Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
NCT02464891	Phase 2	Terminated	Jun 4, 2015	Jul 13, 2017	Atypical Hemolytic Uremic Syndrome
NCT02384317	Phase 2	Completed	Mar 27, 2015	Jun 1, 2018	Immunoglobulin A Nephropathy

Competing Products

5 competing products in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

See all competitors

Product	Company	Stage	Hype Score
Iptacopan + Placebo + Rituximab	Novartis	Phase 2	39
Rituximab + Azathioprine	Roche	Phase 3	40
CCX168 + Midazolam + Celecoxib + Itraconazole + Rifampicin	Amgen	Phase 1	29
CCX168 + Placebo	Amgen	Phase 1	29
[14C]CCX168	Amgen	Phase 1	29